Lavipharm S.A. (ATH:LAVI)
Greece · Delayed Price · Currency is EUR 1.200
-0.020 (-1.64%)
At close: Mar 20, 2026
Lavipharm Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 62.58 | 52.95 | 47.84 | 39.06 | 39.72 | |
Revenue Growth (YoY) | 18.20% | 10.68% | 22.48% | -1.68% | 5.54% |
Cost of Revenue | 32.28 | 27.87 | 25.69 | 21.44 | 23.84 |
Gross Profit | 30.31 | 25.08 | 22.15 | 17.62 | 15.89 |
Selling, General & Admin | - | 20.9 | 18.11 | 15.31 | 14.48 |
Research & Development | - | 0.63 | 0.43 | 0.85 | 0.81 |
Other Operating Expenses | 20.96 | -1.69 | -1.11 | -2.4 | -4.91 |
Operating Expenses | 20.96 | 19.84 | 17.43 | 13.56 | 11.38 |
Operating Income | 9.35 | 5.24 | 4.72 | 4.07 | 4.51 |
Interest Expense | - | -2.01 | -2.17 | -0.72 | -1.83 |
Interest & Investment Income | - | 0.15 | 0.27 | 0.03 | 0.02 |
Currency Exchange Gain (Loss) | - | 0.02 | 0.05 | -0.02 | 0 |
Other Non Operating Income (Expenses) | -1.85 | -0.07 | -0.06 | -0.92 | - |
EBT Excluding Unusual Items | 7.5 | 3.33 | 2.81 | 2.44 | 2.7 |
Gain (Loss) on Sale of Investments | - | -0.24 | -0.48 | - | -0.02 |
Gain (Loss) on Sale of Assets | - | 0.36 | 0.43 | - | - |
Asset Writedown | - | 0.16 | 0.37 | - | 0.11 |
Other Unusual Items | - | - | 0.09 | -0.18 | -0.05 |
Pretax Income | 7.5 | 3.6 | 3.22 | 2.26 | 2.75 |
Income Tax Expense | 2.45 | -5.06 | 1.25 | 1.31 | 1.02 |
Earnings From Continuing Operations | 5.05 | 8.66 | 1.97 | 0.95 | 1.73 |
Earnings From Discontinued Operations | 0.94 | 0.32 | -0.1 | -0.12 | - |
Net Income to Company | 5.99 | 8.98 | 1.87 | 0.83 | 1.73 |
Minority Interest in Earnings | - | 0 | 0 | 0 | -0.01 |
Net Income | 5.99 | 8.98 | 1.87 | 0.83 | 1.72 |
Net Income to Common | 5.99 | 8.98 | 1.87 | 0.83 | 1.72 |
Net Income Growth | -33.31% | 380.06% | 124.34% | -51.60% | -17.72% |
Shares Outstanding (Basic) | - | 168 | 168 | 22 | 17 |
Shares Outstanding (Diluted) | - | 168 | 168 | 22 | 17 |
Shares Change (YoY) | - | 0.17% | 681.40% | 26.42% | - |
EPS (Basic) | - | 0.05 | 0.01 | 0.04 | 0.10 |
EPS (Diluted) | - | 0.05 | 0.01 | 0.04 | 0.10 |
EPS Growth | - | 379.94% | -71.35% | -61.71% | -17.72% |
Free Cash Flow | - | -5 | -3.77 | -32.27 | 2.19 |
Free Cash Flow Per Share | - | -0.03 | -0.02 | -1.50 | 0.13 |
Dividend Per Share | - | 0.020 | - | - | - |
Gross Margin | 48.42% | 47.37% | 46.30% | 45.12% | 40.00% |
Operating Margin | 14.94% | 9.90% | 9.86% | 10.41% | 11.35% |
Profit Margin | 9.57% | 16.96% | 3.91% | 2.14% | 4.34% |
Free Cash Flow Margin | - | -9.45% | -7.87% | -82.63% | 5.52% |
EBITDA | 13.18 | 9.07 | 8.27 | 4.96 | 5.36 |
EBITDA Margin | 21.06% | 17.13% | 17.30% | 12.69% | 13.48% |
D&A For EBITDA | 3.83 | 3.83 | 3.56 | 0.89 | 0.85 |
EBIT | 9.35 | 5.24 | 4.72 | 4.07 | 4.51 |
EBIT Margin | 14.94% | 9.90% | 9.86% | 10.41% | 11.35% |
Effective Tax Rate | 32.69% | - | 38.78% | 57.95% | 37.09% |
Revenue as Reported | 62.58 | - | - | - | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.